A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Abstract Background Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal ne...

Full description

Bibliographic Details
Main Authors: Maximilian Mastall, Patrick Roth, Andrea Bink, Angela Fischer Maranta, Heinz Läubli, Andreas Felix Hottinger, Thomas Hundsberger, Denis Migliorini, Adrian Ochsenbein, Katharina Seystahl, Lukas Imbach, Tibor Hortobagyi, Leonhard Held, Michael Weller, Hans-Georg Wirsching
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
Epilepsy
Gabapentin
Sulfasalazine
Memantine
Cancer neuroscience
Online Access:https://doi.org/10.1186/s12885-023-11797-z

Internet

https://doi.org/10.1186/s12885-023-11797-z

Similar Items